𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine

✍ Scribed by Rossini, P M; Pasqualetti, P; Pozzilli, C; Grasso, M G; Millefiorini, E; Graceffa, A; Carlesimo, G A; Zibellini, G; Caltagirone, C

Book ID
118040655
Publisher
SAGE Publications
Year
2001
Tongue
English
Weight
107 KB
Volume
7
Category
Article
ISSN
1352-4585

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Rituximab in patients with primary progr
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 158 KB πŸ‘ 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

Glatiramer acetate in primary progressiv
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
✍ Jerry S. Wolinsky; Ponnada A. Narayana; Paul O'Connor; Patricia K. Coyle; Corey πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 349 KB πŸ‘ 2 views

## Abstract ## Objective To determine whether glatiramer acetate (GA) slows accumulation of disability in primary progressive multiple sclerosis. ## Methods A total of 943 patients with primary progressive multiple sclerosis were randomized to GA or placebo (PBO) in this 3‐year, double‐blind tri